COVID-19

Hologic Announces Financial Results for First Quarter of Fiscal 2024

– Revenue of $1,013.1 Million, GAAP Diluted EPS of $1.03, and Non-GAAP Diluted EPS of $0.98; All Exceed Guidance –…

2 years ago

Taglich Brothers Initiates Coverage of Cosmos Health Inc.

CHICAGO, IL / ACCESSWIRE / February 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 years ago

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

Innovative approaches in MRI technology demonstrate the potential of portable ultra-low-field MR brain imaging to aid physicians in the diagnosis…

2 years ago

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

Innovative approaches in MRI technology demonstrate the potential of portable ultra-low-field MR brain imaging to aid physicians in the diagnosis…

2 years ago

CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira’s Products

Correction: Extended clarification.HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide…

2 years ago

Corporate Update on Clinical Evaluation of MedMira’s Products

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update…

2 years ago

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live…

2 years ago

Panbela Announces Closing of Approximately $9.0 Million Public Offering

MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of…

2 years ago

Legacy Novozymes delivers solid last full-year results

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales…

2 years ago